This summary is generated by an algorithm. If you find any mistakes, let us know.

Asia Biotechnology Clinical Trials Health Care Pharmaceutical

Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing

– Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced the completion of an oversubscribed $230 million Series C financing.
– This financing round brings Clover’s total capital raised in the last 12 months to over $400 million (over RMB 2.5 billion).
– The Series C round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed and existing investor Delos Capital.
– The proceeds will support the continued development and expansion of Clover’s pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag© technology platform.

Asia Biotechnology Emergency Medicine Pharmaceutical

AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection Programs

– AnchorDx announced the completion of a $40m Series C financing round.
– The round was led by OrbiMed and WuXi Huiying Investment.
– The company plans to use the new funds to accelerate the registration and commercialization of its NGS-based products for single-cancer, multi-cancer, and pan-cancer screening and early detection. The company also plans to deploy its technology to other major disease areas.

Biotechnology Europe Health Care Pharmaceutical

Evox Therapeutics Closes £69.2M Series C Financing

– Evox Therapeutics from Oxford closed $95.4m Series C funding.
– The round was led by Redmile Group with participation from new investors OrbiMed and Invus and existing investors Oxford Sciences Innovation (OSI), GV (formerly Google Ventures) and Cowen Healthcare Investments.
– The company intends to use the funds to advance its exosome-based therapeutics pipeline, including progression of several rare disease assets into the clinic, and continued development of its DeliverEXTM exosome drug platform.

Asia Biotechnology Health Care Pharmaceutical

Sciwind Biosciences Secures US$37 Million Series B Financing

– Sciwind biosciences secured US$37m series B financing.
– The financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.
– Sciwind focuses on research and development of innovative biologics in the therapeutic area of chronic metabolic and immunological diseases and has driven multiple projects into clinical trials.
– Two more IND applications are expected to be filed in 2021 including an oral formulation of a highly active GLP-1 analogue.

Biotechnology Health Care Medical North America Pharmaceutical Therapeutics

Elicio Therapeutics Secures a Total of $73 Million in Series B Financing

– Elicio Therapeutics secured a total of $73m in Series B financing.
– The funding was established from an international investor base, including multiple strategic and institutional investors.
– Proceeds will advance Elicio’s lead program ELI-002 into clinical trials in early 2021 for mutated KRAS (mKRAS) driven cancers, estimated to be 25% of all human solid tumors.
– ELI-002 contains two powerful components: The company’s proprietary immune stimulating Amphiphile (AMP)-CpG, an adjuvant, and AMP mKRAS peptides which target a broad spectrum of KRAS mutations that drive 97% of all KRAS-driven cancers.

Biotechnology North America Pharmaceutical Therapeutics

Iterion Therapeutics Lands $17M Series B

– Iterion Therapeutics, a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, has raised $17m in a Series B financing.
РThe round was led by Lumira Ventures, with the participation of existing investors, including Sant̩ Ventures, as well as new investors Venture Investors, GPG Ventures, and Viva BioInnovator.

Chemical Manufacturing North America Pharmaceutical

Phlow Raises $20M in Series A Financing

– Phlow Corp., a public benefit corporation providing access to essential medicines, closed a $20m Series A funding.
– The company intends to use the funds to build its commercial business team, establish its commercial business unit’s data and analytics platforms, advance the commercial research and development of APIs and finished pharmaceutical products, and fund innovative initiatives to improve the delivery of essential medicines.
– Led by Eric Edwards, M.D., Ph.D., co-founder, president and CEO, Phlow is using advanced manufacturing processes leveraging flow chemistry to produce active pharmaceutical ingredients (APIs) and finished pharmaceutical products.

Biotechnology Europe Medical Medical Device Pharmaceutical

OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

– OSE Immunotherapeutics entered a loan agreement of up to €25 million with the European Investment Bank.
– The loan facility is divided into three tranches including two tranches of €10 million each and a third tranche of €5 million.

North America Pharmaceutical

Pipeline Therapeutics Completes $80 Million Series C Financing

– Pipeline Therapeutics completed an $80m Series C financing round.
– The round was led by a healthcare-focused new investor, with participation by other new investors including Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital, Red Tree Venture Capital, and an undisclosed leading global investment fund.
– All of the company’s existing shareholders, including founding investor Versant Ventures, Sectoral Asset Management and Cleva Pharma (a Brace Pharma affiliate), participated in the round.
– Pipeline Therapeutics plans to use the proceeds to advance its development candidates PIPE-505, in patients with sensorineural hearing loss, and PIPE-307, in patients with multiple sclerosis. Proceeds will also be used to advance additional therapeutic candidates and for general corporate purposes.

Biopharma Biotechnology Health Care Medical North America Pharmaceutical

Day One Biopharmaceuticals Inks $130M Series B Financing

– Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating therapies for children and adults with cancer, announced a $130 million Series B financing.
– The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.

1 2
Crunchbase icon

Content report

The following text will be sent to our editors: